65130-46-3

Usage

Uses

Used in Organic Synthesis:
1-(2-Bromoethyl)-4-fluorobenzene is used as a reagent for the synthesis of more complex organic molecules. Its unique structure allows for various chemical reactions, making it a valuable component in the creation of new compounds.
Used in Pharmaceutical Industry:
1-(2-Bromoethyl)-4-fluorobenzene is used as a building block in the development of pharmaceutical compounds. Its versatility in organic synthesis enables the production of potential drug candidates with specific therapeutic properties.
Used in Chemical Research:
1-(2-Bromoethyl)-4-fluorobenzene is used as a research tool in chemical studies. Its properties and reactivity provide insights into the behavior of similar compounds and contribute to the understanding of chemical reactions and mechanisms.
Used in Material Science:
1-(2-Bromoethyl)-4-fluorobenzene is used as a component in the development of new materials with specific properties. Its incorporation into polymers or other materials can result in materials with tailored characteristics for various applications.

Upstream product

• 52780-14-0 1-(3-bromophenyl)ethanol 
• 405-99-2 para-fluorostyrene 
• 403-42-9 1-(4-fluorophenyl)ethanone 
• 462-06-6 fluorobenzene 
• 403-41-8 1-(4-Fluorophenyl)ethanol 
• 459-47-2 1-ethyl-4-fluorobenzene 

Downstream Products

• 403-41-8 1-(4-Fluorophenyl)ethanol 
• 2928-12-3 rac-1-(4-fluorophenyl)ethyl acetate 
• 1000887-16-0 C₂₉H₂₈FN₃O₅S 
• 1000887-17-1 C₂₉H₂₈FN₃O₅S 
• 672293-44-6 1RS-[1-(4-fluoro-phenyl)-ethyl]-3R-methyl-piperazine 
• 1076195-30-6 C₁₃H₁₉FN₂ 
• 1115389-44-0 C₁₅H₁₁FN₂O₂ 
• 1109230-26-3 5-bromo-2-[1-(4-fluorophenyl)ethyl]-3,4-dihydroisoquinolin-1(2H)-one 
• 1064708-35-5 N-(1-(4-fluorophenyl)ethyl)-4-benzoylmethyl-4-piperidinol hydrochloride 
• 862270-46-0 4-[(1S,1R)-1-(4-fluorophenyl)ethyl]piperazine-1-carboxylic acid tert-butyl ester 
• 1450652-63-7 N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-(1-(4-fluorophenyl)ethyl)-2-methyl-1H-indole-3-carboxamide 
• 403-42-9 1-(4-fluorophenyl)ethanone 

Relevant academic research and scientific papers

NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS

The invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by mycobacterium, such as tuberculosis.

AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS

Compounds having formula (I) (IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).

Transition-Metal-Free Stereospecific Cross-Coupling with Alkenylboronic Acids as Nucleophiles

We herein report a transition-metal-free cross-coupling between secondary alkyl halides/mesylates and aryl/alkenylboronic acid, providing expedited access to a series of nonchiral/chiral coupling products in moderate to good yields. Stereospecific SN2-type coupling is developed for the first time with alkenylboronic acids as pure nucleophiles, offering an attractive alternative to the stereospecific transition-metal-catalyzed C(sp2)-C(sp3) cross-coupling.

Catalytic Carbocation Generation Enabled by the Mesolytic Cleavage of Alkoxyamine Radical Cations

A new catalytic method is described to access carbocation intermediates via the mesolytic cleavage of alkoxyamine radical cations. In this process, electron transfer between an excited state oxidant and a TEMPO-derived alkoxyamine substrate gives rise to a radical cation with a remarkably weak C?O bond. Spontaneous scission results in the formation of the stable nitroxyl radical TEMPO.as well as a reactive carbocation intermediate that can be intercepted by a wide range of nucleophiles. Notably, this process occurs under neutral conditions and at comparatively mild potentials, enabling catalytic cation generation in the presence of both acid sensitive and easily oxidized nucleophilic partners.

Scalable anti-Markovnikov hydrobromination of aliphatic and aromatic olefins

To improve access to a key synthetic intermediate we targeted a direct hydrobromination-Negishi route. Unsurprisingly, the anti-Markovnikov addition of HBr to estragole in the presence of AIBN proved successful. However, even in the absence of an added initiator, anti-Markovnikov addition was observed. Re-examination of early reports revealed that selective Markovnikov addition, often simply termed "normal" addition, is not always observed with HBr unless air is excluded, leading to the rediscovery of a reproducible and scalable initiator-free protocol.

MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF

Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.

NOVEL TRPV3 MODULATORS

Disclosed herein are modulators of TRPV3 of formula (I) wherein G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, u, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

Substituted Cyclic Carboxamide and Urea Derivatives as Ligands of the Vanilloid Receptor

Substituted cyclic carboxamide and urea compounds, a process for their preparation, pharmaceutical compositions containing these compounds, and the use of these compounds for the treatment and/or inhibition of pain and other conditions mediated by the vanilloid receptor 1.

1-OXO-ISOINDOLINE-4-CARBOXAMIDE AND 1-OXO-1,2,3,4-TETRAHYDROISOQUINOLINE-5-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF

The present invention relates to derivatives of 1-oxo-isoindoline-4-carboxamides and of 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamides, to the preparation thereof and to the therapeutic use thereof.

ANTI-VIRAL COMPOUNDS

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.